In the MAPK signaling pathway, phosphorylation levels of MEK1/2 were reduced without significant differences in TAAD patients, and comparable p-ERK1/2, p-JNK1/2, and p-P38 levels were observed in the aortas of CAD and TAAD individuals (Fig. 5c). This evidence concerns the gene MAPK3 and coronary artery disorder.